Drug Alert: 51 Drug samples fail to qualify CDSCO test
In its latest drug alert, the apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO), has flagged 51 medicine batches for failing to qualify for a random drug sample test for the month of July, while three drug samples have been declared spurious.
The list of Drugs declared as Not of Standard Quality includes Stadmed's Paracin Plus Suspension (Ibuprofen and Paracetamol Suspension), Hindustan Antibiotics' Ornidazole and Ofloxacin Tablets IP, Alves Healthcare's Rabeprazole Gastro-Resistant Tablets IP 20 mg, Zee Laboratories' Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg, Zenith Drugs' Cyproheptadine Hydrochloride Syrup IP (Hungree Syrup), and others.
For more details, check out the link given below:
Drug Alert: 53 Drug Samples Fail To Qualify CDSCO Test, 3 Declared Spurious
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.